CBComfort A. Boateng

Comfort A. Boateng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Comfort A. Boateng has a total of 161 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas M. Keck

    Department of Chemistry and Biochemistry, Rowan University, 201 Mullica Hill Road, Glassboro, New Jersey, USA

    10 shared publications
  • Amy Hauck Newman

    Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, United States

    6 shared publications
  • Alessandro Bonifazi

    Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse ─ Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States

    5 shared publications
  • Barbara S. Slusher

    Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    5 shared publications
  • Norman Nguyen

    Department of Chemistry & Biochemistry, Department of Biological & Biomedical Sciences, College of Science and Mathematics, Rowan University, 201 Mullica Hill Road, Glassboro, NJ 08028, United States

    5 shared publications
  • Rana Rais

    Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

    5 shared publications

Latest Publications

  • Open Access

    Novel dopamine 4 receptor ligands differentially ameliorate ADHD-like behaviors in spontaneously hypertensive rats

    by Ike C. de la Peña, Samantha Andino, Ashley Amis, Mohammad A. Alkhatib, Tian Li, Thomas M. Keck, Comfort A. Boateng

    Rationale: : Dopamine D4 receptors (D4Rs) have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD), yet their precise role and therapeutic relevance remain underexplored. Highly selective D4R compounds may provide a valuable tool to elucidate D4R function and assess their potential as non-stimulant ADHD treatments. Objectives: This study examined the behavioral effects of two novel D4R drugs, namely, FMJ-01-38 (high-efficacy partial agonist) and FMJ-01-54 (full antagonist) in adolescent spontaneously hypertensive rats (SHR/NCrl), a validated ADHD animal model, and Wistar (control) rats. Methods: Rats received intraperitoneal injections of FMJ-01-38 or FMJ-01-54 (5–10 mg/kg), or vehicle prior to behavioral assays assessing locomotor activity (open field tests), recognition memory (novel object preference test), spatial working memory (Y-maze test), and impulsivity (delay discounting task). Results: FMJ-01-38 dose-dependently reduced locomotor hyperactivity and improved spontaneous alternation in SHR/NCrl; at 5 mg/kg, it also enhanced novel object preference and reduced impulsive choice and action, indicating attenuation of ADHD-like behaviors and improved cognitive function. FMJ-01-54 produced similar improvements in Y-maze and novel-object performance without altering locomotor activity or impulsivity of SHR/NCrl, suggesting selective cognitive improvement. In Wistar rats, FMJ-01-38 increased novel object preference only at the 5 mg/kg dose, while FMJ-01-54 treatment did not produce any significant behavioral effects. Conclusions: These findings demonstrate that D4R modulation, through either partial agonism or antagonism, differentially ameliorates ADHD-related behaviors and improves cognitive performance. Both FMJ-01-38 and FMJ-01-54 produced minimal effects in control animals, suggesting pathology-specific efficacy and highlighting D4R ligands as promising non-stimulant therapeutic candidates for ADHD.

  • Open Access

    Investigating substituted phenylacetamide ligands in the D4R extended binding pocket

    by Tian Li, Mohammad Alkhatib, Peter A. Ramdhan, Lindsay Bourn, Jane K. Rainwater, Norman Nguyen, Caitlin P. Farrington, Blake Lewis, Chenglong Li, Thomas M. Keck, et al.

  • Open Access

    Investigating Substituted Phenylacetamide Ligands in the D4R Extended Binding Pocket

    by Tian Li, Mohammad Alkhatib, Peter A. Ramdhan, Lindsay A. Bourn, Jane K. Rainwater, Norman Nguyen, Caitlin P. Farrington, Blake Lewis, Chenglong Li, Thomas M. Keck, et al.

    Preclinical studies indicate that selective targeting of D4R may improve behavioral and cognitive outcomes in animal models relevant to cognitive disorders, like ADHD and Alzheimer’s disease, and substance use disorders (SUDs). In this study, we extend upon prior development of analogs of A-412997, a D4R-selective partial agonist, by exploring ligand interactions within the secondary binding pocket. We modified the alkyl chain on the phenylacetamide’s benzyl ring by extending and cyclizing the alkyl chain. A series of compounds were synthesized and tested using competition radioligand binding assays on D2R, D3R, and D4R, using [3H]N-methylspiperone as the competing radioligand. Herein, we report that while increasing the chain length beyond two carbons reduced D4R affinity and selectivity, cyclizing the alkyl chain enhanced D4R affinity and maintained selectivity over D2R and D3R by 120-fold or more. Molecular modeling results suggest that the cyclized rings engage in more favorable interactions within the D4R binding pocket.

  • Open Access

    Bioisosteric Replacement of Amides with 1,2,3-Triazoles Improves Dopamine D4 Receptor Ligand Pharmacokinetics

    by Mohammad Alkhatib, Franziska M. Jakobs, John N. Hanson, Ashley N. Nilson, Amy E. Moritz, Tian Li, Afua B. Faibille, Lindsay A. Bourn, Peter A. Ramdhan, Joseph Ricchezza, et al.

    Dopamine D4 receptor (D4R) signaling affects decision-making, memory formation, cognition, and attention. Previously developed D4R-selective ligands were metabolically unstable in vivo due to amide bond linker hydrolysis. In this study, analog compounds were synthesized using click chemistry, bioisosterically replacing amides with a 1,2,3-triazole linker. Herein, we report 1,2,3-triazole analogs maintained high D4R affinity and subtype selectivity but had slightly reduced functional efficacy in cAMP and β-arrestin recruitment assays. Using rat and human liver microsomes to evaluate phase I metabolism, we determined that amide ligands were more metabolically unstable in rat microsomes, and the triazole substitutions enhanced compound stability. Four compounds were evaluated in rat pharmacokinetics studies. In particular, 17 (antagonist) and 18 (low-efficacy partial agonist) had desirable results in plasma half-life and brain exposure measures. These new analogs are suitable for behavioral studies in rats and represent improved molecular tools to further explore D4R signaling in rodent models.


  • Open Access

    Investigating Substituted Phenylacetamide Ligands in the D4R Extended Binding Pocket

    by Tian Li, Mohammad Alkhatib, Peter Ramdhan, Lindsay Bourn, Jane Rainwater, Norman Nguyen, Caitlin Farrington, Blake Lewis, Chenglong Li, Thomas Keck, et al.

    Preclinical studies indicate that selective targeting of D4R may improve behavioral and cognitive outcomes in animal models relevant to cognitive disorders, like ADHD and Alzheimer’s disease, and substance use disorders (SUDs). In this study, we extend upon prior development of analogs of A-412997, a D4R-selective partial agonist, by exploring ligand interactions within the secondary binding pocket. We modified the alkyl chain on the phenylacetamide’s benzyl ring by extending and cyclizing the alkyl chain. A series of compounds were synthesized and tested using competition radioligand binding assays on D2R, D3R, and D4R, using [3H]N-methylspiperone as the competing radioligand. Herein, we report that while increasing the chain length beyond two carbons reduced D4R affinity and selectivity, cyclizing the alkyl chain enhanced D4R affinity and maintained selectivity over D2R and D3R by 120-fold or more. Molecular modeling results suggest that the cyclized rings engage in more favorable interactions within the D4R binding pocket.

  • Open Access

    Novel Dopamine 4 Receptor Ligands Differentially Ameliorate ADHD-like Behaviors in Spontaneously Hypertensive Rats

    by Ike C. de la Peña, Samantha Andino, Ashley Amis, Mohammad A. Alkhatib, Tian Li, Thomas M. Keck, Comfort A. Boateng

    Rationale: Dopamine D4 receptors (D4Rs) have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD), yet their precise role and therapeutic relevance remain underexplored. Highly selective D4R compounds may provide a valuable tool to elucidate D4R function and assess their potential as non-stimulant ADHD treatments. Objectives: This study examined the behavioral effects of two novel D4R drugs, namely, FMJ-01-38 (high-efficacy partial agonist) and FMJ-01-54 (full antagonist) in adolescent spontaneously hypertensive (SHR/NCrl) rats, a validated ADHD model, and Wistar controls. Methods: Rats received intraperitoneal FMJ-01-38 or FMJ-01-54 (5–10 mg/kg) or vehicle prior to behavioral assays assessing locomotor activity (open field tests), recognition memory (novel object preference), attention and working memory (Y-maze test), and impulsivity (delay discounting task). Results: FMJ-01-38 dose-dependently reduced locomotor hyperactivity and improved spontaneous alternation behavior in SHR/NCrl; at 5 mg/kg it enhanced novel-object preference and decreased impulsive choice and action, indicating attenuation of ADHD-like symptoms and cognitive enhancement. FMJ-01-54 produced similar improvements in Y-maze and novel-object performance without altering locomotor activity or impulsivity of SHR/NCrl, suggesting selective cognitive improvement. In Wistar rats, FMJ-01-38 increased novel-object preference only at the 5 mg/kg dose, while FMJ-01-54 treatment did not produce any significant behavioral effects. Conclusions: These findings demonstrate that D4R modulation, through either partial agonism or antagonism, differentially ameliorates ADHD-related behaviors. Both FMJ-01-38 and FMJ-01-54 produced minimal effects in control animals, suggesting pathology-specific efficacy and highlighting D4R ligands as promising non-stimulant therapeutic candidates for ADHD.

  • Open Access

    Bioisosteric Replacement of Amides with 1,2,3-Triazoles Improves Dopamine D4 Receptor Ligand Pharmacokinetics

    by Mohammad Alkhatib, Franziska M. Jacobs, John N. Hanson, Ashley N. Nilson, Amy E. Moritz, Tian Li, Afua B. Faibille, Lindsay A. Bourn, Peter A. Ramdhan, Joseph Ricchezza Iv, et al.

    Dopamine D4 receptor (D4R) signaling affects decision-making, memory formation, cognition, and attention. Previously developed D4R-selective ligands were metabolically unstable in vivo due to amide bond linker hydrolysis. In this study, analog compounds were synthesized using click chemistry, bioisosterically replacing amides with a 1,2,3-triazole linker. Herein, we report 1,2,3-triazole analogs maintained high D4R affinity and subtype selectivity while retaining their functional activity. Using rat and human liver microsomes to evaluate phase I metabolism, we determined that amide ligands were more metabolically unstable in rat microsomes, and the triazole substitutions enhanced compound stability. Four compounds were evaluated in rat pharmacokinetics studies. In particular, 17 (antagonist) and 18 (low-efficacy partial agonist) had desirable results in plasma half-life and brain exposure measures. These new analogs are suitable for behavioral studies in rats and represent improved molecular tools to further explore D4R signaling in rodent models.


  • Open Access

    Development of novel tools for dissection of central versus peripheral dopamine D 2 -like receptor signaling in dysglycemia

    by Alessandro Bonifazi, Michael Ellenberger, Zachary J. Farino, Despoina Aslanoglou, Rana Rais, Sandra Pereira, José O. Mantilla-Rivas, Comfort A. Boateng, Amy J. Eshleman, Aaron Janowsky, et al.

    Dopamine (DA) D 2 -like receptors in both the central nervous system (CNS) and the periphery are key modulators of metabolism. Moreover, disruption of D 2 -like receptor signaling is implicated in dysglycemia. Yet, the respective metabolic contributions of CNS versus peripheral D 2 -like receptors including D 2 (D2R) and D 3 (D3R) receptors remain poorly understood. To address this, we developed new pharmacological tools, D 2 -like receptor agonists with diminished and delayed blood-brain barrier capability, to selectively manipulate D2R/D3R signaling in the periphery. We designated bromocriptine methiodide (BrMeI), a quaternary methiodide analogue of D2/3R agonist and diabetes drug bromocriptine, as our lead compound based on preservation of D2R/D3R binding and functional efficacy. We then used BrMeI and unmodified bromocriptine to dissect relative contributions of CNS versus peripheral D2R/D3R signaling in treating dysglycemia. Systemic administration of bromocriptine, with unrestricted access to CNS and peripheral targets, significantly improved both insulin sensitivity and glucose tolerance in obese, dysglycemic mice in vivo . In contrast, metabolic improvements were attenuated when access to bromocriptine was restricted either to the CNS through intracerebroventricular administration or delayed access to the CNS via BrMeI. Our findings demonstrate that the coordinated actions of both CNS and peripheral D 2 -like receptors are required for correcting dysglycemia. Ultimately, the development of a first-generation of drugs designed to selectively target the periphery provides a blueprint for dissecting mechanisms of central versus peripheral DA signaling and paves the way for novel strategies to treat dysglycemia.

  • Open Access

    Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder

    by Comfort A. Boateng, Ashley N. Nilson, Rebekah Placide, Mimi L. Pham, Franziska M. Jakobs, Noelia Boldizsar, Scot McIntosh, Leia S. Stallings, Ivana V. Korankyi, Shreya Kelshikar, et al.

    Pharmacological targeting of the dopamine D4 receptor (D4R)─expressed in brain regions that control cognition, attention, and decision-making─could be useful for several neuropsychiatric disorders including substance use disorders (SUDs). This study focused on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.9 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Novel analogue 16f is a potent low-efficacy D4R partial agonist, metabolically stable in rat and human liver microsomes, and has excellent brain penetration in rats (AUCbrain/plasma > 3). 16f (5-30 mg/kg, i.p.) dose-dependently decreased iv cocaine self-administration in rats, consistent with previous results produced by D4R-selective antagonists. Off-target antagonism of 5-HT2A or 5-HT2B may also contribute to these effects. Results with 16f support further efforts to target D4R in SUD treatment.


  • Open Access

    Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder

    by Comfort A. Boateng, Ashley N. Nilson, Rebekah Placide, Mimi L. Pham, Franziska M. Jakobs, Noelia Boldizsar, Scot McIntosh, Leia S. Stallings, Ivana V. Korankyi, Shreya Kelshikar, et al.

    The dopamine D4 receptor (D4R), a G protein-coupled receptor, is predominantly expressed in brain regions that control cognition, attention, and decision making. Previous studies have indicated that D4R-targeted ligands could be promising therapeutic targets for the treatment of several neuropsychiatric conditions, including substance use disorders (SUDs). There are currently no FDA-approved medications that selectively target D4Rs. New ligands may facilitate better understanding of the role of D4R-mediated signaling in drug-taking and drug-seeking behaviors. The present study focuses on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.87 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Based on receptor affinity and functional analyses, 5f was identified as a potent low-efficacy partial agonist of the D4R and selected for further investigation. 5f was metabolically stable in rat and human liver microsome assays and displayed excellent brain penetration in rats. Using a within-session multidosing procedure, 5f (5, 15 and 30 mg/kg, i.p.) dose-dependently decreased i.v. infusions of three-unit doses of cocaine under a fixed-ratio (FR) FR3 schedule of reinforcement. These results are consistent with previous results produced by D4R-selective antagonists in SUD models, however off-target antagonism of 5-HT2A or 5-HT2B receptors may also contribute to these effects. Results with compound 5f support further efforts to target D4R in the treatment of SUDs. Further development of the benzothiazole scaffold may engineer out any serotonergic activity.